申请人:ALDEYRA THERAPEUTICS, INC.
公开号:US20150335632A1
公开(公告)日:2015-11-26
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
本发明提供了一种使用初级胺清除有毒醛类物质,如MDA和HNE,以治疗、预防和/或减少涉及醛毒性的疾病、疾病和疾病的风险,包括眼部疾病、皮肤疾病、与水泡剂有害影响相关的疾病、自身免疫、炎症、神经和心血管疾病。